Abrupt withdrawal of Chlorpromazine and Thioridazine from Schizophrenic In-Patients
Canadian Psychiatric Association Journal · 1966-10 · 11 (5) · 410-413
DOI: 10.1177/070674376601100507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Psychiatric Association Journal, online erschienen am 26.04.2017. Verfasst von W. T. Melnyk und 2 weiteren Autor:innen. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
In this study forty patients were randomly assigned to either a Continuation of Thioridazine or Chlorpromazine Medication Group or to a Placebo Medication Group. Withdrawal symptoms were recorded in a large majority of the Placebo Group. Characteristically, these symptoms no longer occurred after the second week of withdrawal. Symptoms which characterized the patient's illness prior to phenothiazine treatment were observed in 50 per cent of the Placebo Group by the end of the six weeks' withdrawal period. None of the Drug Group showed relapse symptoms.
Zitieren
APA
Melnyk, W. T., Worthington, A. G., & Laverty, S. G. (1966). Abrupt withdrawal of Chlorpromazine and Thioridazine from Schizophrenic In-Patients. Canadian Psychiatric Association Journal, 11(5), 410-413. https://doi.org/10.1177/070674376601100507
Vancouver
Melnyk WT, Worthington AG, Laverty SG. Abrupt withdrawal of Chlorpromazine and Thioridazine from Schizophrenic In-Patients. Canadian Psychiatric Association Journal. 1966;11(5):410-413. doi:10.1177/070674376601100507
BibTeX
@article{Melnyk1966,
author = {Melnyk, W. T. and Worthington, A. G. and Laverty, S. G.},
title = {Abrupt withdrawal of Chlorpromazine and Thioridazine from Schizophrenic In-Patients},
journal = {Canadian Psychiatric Association Journal},
year = {1966},
volume = {11},
number = {5},
pages = {410--413},
doi = {10.1177/070674376601100507}
}
EUVIMED